<DOC>
	<DOCNO>NCT01721941</DOCNO>
	<brief_summary>The primary objective phase I dose escalation study determine maximum tolerate dose TH-302 administer doxorubicin via trans-arterial chemo-embolization ( TACE ) patient hepatocellular carcinoma ( HCC ) transplant candidate unresectable disease . HCC second lead cause worldwide cancer death generally incurable without liver transplant . TACE convert 40 % patient transplant candidate . Additionally , non-transplant HCC patient , TACE confer statistical improvement overall survival . Selective HCC arterial catheterization TACE allow delivery concentrate drug liver tumor optimal TACE chemotherapy regimen yet determine . TH-302 hypoxia inducible agent activate hypoxic environment induce TACE .</brief_summary>
	<brief_title>TH-302 Plus Doxorubicin Delivered Trans-Arterial Chemoembolization ( TACE ) Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>Transarterial chemoembolization ( TACE ) major modality utilized tumor downstaging transplant local therapy non-transplant patient . This procedure allow delivery concentrate drug tumor , follow embolization eliminates blood supply create environment hypoxia . The process induces tumor ischemia , achieve drug concentration tumor 10 25 time great achieve infusion . A hypoxic microenvironment characteristic many solid tumor include hepatocellular cancer , induce TACE . The hypoxia-activated prodrug , TH-302 , design selectively physiologically target hypoxic microenvironment . While doxorubicin cisplatin use drug TACE among agent , none stand optimal agent target HCC . Because action TH-302 hypoxia , agent mechanistic advantage agent TACE . The current study design assess potential therapeutic benefit add TH-302 standard doxorubicin base TACE regimen patient advance hepatocellular carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>At least 18 year age Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee Patients hepatocellular carcinoma either : 1. liver limit disease transplant candidate fall outside Milan criterion , may eligible transplant successful downstaging TACE 2. liver limit disease satisfy Milan criterion , risk fall Milan criterion receive liver transplant 3. nontransplantable HCC liver limit metastatic disease require local TACE therapy Measurable disease modify RECIST criterion ( least one target lesion outside previous radiation field ) ECOG performance status 2 less Life expectancy least 3 month ChildsPugh Class A B HCC amenable TACE Patent main portal vein ( thrombosis portal vein branch exclusionary ) Acceptable liver function : Bilirubin &lt; 2 mg/dL AST ( SGOT ) ALT ( SGPT ) &lt; 5 x ULN allow Acceptable renal function : Serum creatinine &lt; 1.5 ULN Acceptable hematologic status ( without hematologic support TACE # 1 ) : ANC &gt; 500 cells/μL Platelet count &gt; 50,000/μL New York Heart Association ( NYHA ) Class III IV , cardiac disease , myocardial infarction within 6 month prior Day 1 , unstable arrhythmia symptomatic peripheral arterial vascular disease Known brain , leptomeningeal epidural metastasis ( unless treat well control &gt; =3 month ) Previously treat malignancy , except adequately treat nonmelanoma skin cancer , situ cancer , cancer subject diseasefree least 5 year Severe chronic obstructive pulmonary disease hypoxemia ( require supplementary oxygen , symptom due hypoxemia oxygen saturation &lt; 90 % pulse oximetry 2 minute walk ) opinion investigator physiological state likely cause systemic regional hypoxemia Major surgery , diagnostic surgery , within 4 week prior Day 1 , without complete recovery Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Sorafenib within previous 4 week intention initiate sorafenib study Poor liver function indicate serum bilirubin &gt; 2 mg/dL , ChildPugh Class C , severe coagulopathy ( INR &gt; 2 ) correctable vitamin K , active hepatic encephalopathy Main portal vein occlusion Liver rupture tumor penetration liver capsule Tumor invasion biliary system biliary obstruction Severe cytopenia , include ANC &lt; 500 cells/μL , Hemoglobin &lt; 8 g/dL , platelet &lt; 50,000/μL Subjects exhibit allergic reaction structural compound , biological agent similar TH302 Females pregnant breastfeeding Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk subject study Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>liver cancer</keyword>
	<keyword>hepatoma</keyword>
	<keyword>TACE</keyword>
	<keyword>transarterial chemoembolization</keyword>
	<keyword>TH302</keyword>
</DOC>